No Established Safe Dose Not a Protocol
FDA · TGA · WADA · peer-reviewed literature Updated May 2026 Reviewed by Allmeds AI Pharmacist

BPC-157 Dosage: Why No Safe Human Dose Has Been Established

Online sources post a variety of BPC-157 dosing protocols. These are not regulator-validated. The FDA has not approved BPC-157 for any therapeutic use, and no controlled human trial has established a safe and effective dose for any marketed indication. This page does not publish a protocol; it explains why no safe dose has been established.

No safe and effective human dose of BPC-157 has been established by any regulator. BPC-157 is not FDA-approved. The FDA has flagged it for significant safety concerns when compounded. Dosing protocols on online sources are derived from animal studies and anecdotal use, not from controlled human trials. Allmeds does not publish dosing protocols for unapproved peptides.

Key Takeaways

  • No regulator has established a safe and effective human dose for BPC-157.
  • Online dosing protocols are derived from rat-model studies and anecdotal use, not from controlled human trials.
  • The FDA has identified BPC-157 among compounded substances that may present significant safety risks.
  • Dose-response, route differences, and long-term safety are not characterised in any regulator-reviewed dataset.
  • Allmeds does not publish dosing protocols for unapproved peptides. Discuss any planned use with a clinician.

Why this page does not list a BPC-157 dose

A safe and effective human dose of BPC-157 has not been established by any regulator. The FDA has not approved BPC-157 for any therapeutic use. No adequately controlled human trial has defined safe and effective dosing for any marketed indication. Publishing a dose under these conditions would imply a safety floor that is not supported by evidence.

Online sources that post protocols typically derive numbers from rat-model studies (which used specific weight-adjusted doses for short periods in animals) or from anecdotal community use. Neither path produces a regulator-grade safety dataset.

Why rat-study doses don't translate

Animal-to-human dose translation requires controlled clinical trials that characterise pharmacokinetics, dose-response, route differences, and adverse-event profile across human populations. None of this has been done for BPC-157 in any regulator-reviewed dataset. Body-weight scaling shortcuts (e.g. "X µg/kg") are not a substitute for clinical characterisation.

What regulators say about BPC-157

The FDA has identified BPC-157 among compounded substances that may present significant safety risks. The FDA position cites potential immunogenicity, peptide impurity, API characterisation complexity, and absence of safety-related information for proposed routes of administration. The TGA does not list BPC-157 on the ARTG for the promoted uses. WADA prohibits BPC-157.

Check your medications before any change

Allmeds scans interactions across your full list. Free for individuals; team plans available.

Try it free → Talk to Sales

Common Questions

Why don't you publish a BPC-157 dosing protocol?

Because no safe and effective human dose has been established by any regulator. BPC-157 is not FDA-approved. Publishing a dose under these conditions would imply a safety floor that has not been demonstrated.

What dose did the original animal studies use?

Rat studies have used a range of weight-adjusted doses (often in the µg/kg range) administered intraperitoneally or intragastrically for short experimental periods. These are study-specific values from animal models; they do not establish a safe human dose.

Where do online BPC-157 protocols come from?

Online protocols come from anecdotal community use and informal extrapolation from animal-study doses. They are not regulator-reviewed and not supported by controlled human trial data.

Is there any safe way to dose BPC-157?

No regulator-grade answer exists, because no regulator-reviewed dosing study has been done. Anyone considering BPC-157 should discuss the regulator position and the limits of evidence with a clinician before any decision.

References

  1. Sikiric P et al. Brain-gut axis and pentadecapeptide BPC 157. Curr Neuropharmacol. 2016;14(8):857-865. Source.
  2. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
  3. World Anti-Doping Agency. WADA Prohibited List. Source.
  4. Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.
Not medical advice. This page summarises regulator statements and peer-reviewed literature for general information. It is not a substitute for professional medical advice. Speak to your doctor or pharmacist before starting, stopping, or changing any medicine.